Esperer Bioresearch said Thursday it is planning to raise around Rs 25 crore over the next nine months to strengthen and expand its presence in the country and overseas.
The company is looking to set up a lifestyle specific nutra plant in India, besides expanding the global business in onco nutrition, the company said in a statement.
It is also focusing on conducting country-specific clinical studies to take its products outside India, it added.
"We are looking to raise approximately Rs 25 crore in a timeline of next six to nine months," Esperer Bioresearch founder and CEO Raktim Chattopadhyay said.
The company has not raised any funds so far and has adopted internal seed funding, he added.
To address the nutritional deficiencies in cancer patients in India, the company launched two health supplements on Wednesday, Esperer Bioresearch said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
